Brand Name

Almotriptan

View Brand Information
FDA approval date: July 07, 2015
Classification: Serotonin-1b and Serotonin-1d Receptor Agonist
Form: Tablet

What is Almotriptan?

Almotriptan malate tablets are a 5HT 1B/1D receptor agonist indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Correction: In Vivo Evaluation of Almotriptan Malate Formulation Through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment.
Correction: In Vivo Evaluation of Almotriptan Malate Formulation Through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment.
Journal: AAPS PharmSciTech
Published: August 19, 2025
A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy.
A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy.
Journal: Journal of pain research
Published: July 04, 2025
Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system.
Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system.
Journal: PloS one
Published: June 09, 2025
View All Latest Advances